Ad is loading...
CPMV
Price
$0.99
Change
-$0.00 (-0.00%)
Updated
Nov 14 closing price
57 days until earnings call
HLOSF
Price
$1.50
Change
-$0.00 (-0.00%)
Updated
Oct 29 closing price
Ad is loading...

CPMV vs HLOSF

Header iconCPMV vs HLOSF Comparison
Open Charts CPMV vs HLOSFBanner chart's image
Mosaic ImmunoEngineering
Price$0.99
Change-$0.00 (-0.00%)
Volume$1.15K
CapitalizationN/A
HEALIOS K K
Price$1.50
Change-$0.00 (-0.00%)
Volume$12.4K
CapitalizationN/A
CPMV vs HLOSF Comparison Chart
Loading...
View a ticker or compare two or three
VS
CPMV vs. HLOSF commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPMV is a Buy and HLOSF is a Buy.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (CPMV: $0.99 vs. HLOSF: $1.50)
Brand notoriety: CPMV and HLOSF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CPMV: 269% vs. HLOSF: 169%
Market capitalization -- CPMV: $7.17M vs. HLOSF: $108.27M
CPMV [@Biotechnology] is valued at $7.17M. HLOSF’s [@Biotechnology] market capitalization is $108.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPMV’s FA Score shows that 0 FA rating(s) are green whileHLOSF’s FA Score has 0 green FA rating(s).

  • CPMV’s FA Score: 0 green, 5 red.
  • HLOSF’s FA Score: 0 green, 5 red.
According to our system of comparison, HLOSF is a better buy in the long-term than CPMV.

Price Growth

CPMV (@Biotechnology) experienced а +10.00% price change this week, while HLOSF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

CPMV is expected to report earnings on Jan 14, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
HLOSF($108M) has a higher market cap than CPMV($7.17M). CPMV YTD gains are higher at: 65.000 vs. HLOSF (-5.363). CPMV has higher annual earnings (EBITDA): -1.13M vs. HLOSF (-2.39B). HLOSF has more cash in the bank: 8.89B vs. CPMV (3.73K). CPMV has less debt than HLOSF: CPMV (1.41M) vs HLOSF (6.1B). HLOSF has higher revenues than CPMV: HLOSF (521M) vs CPMV (0).
CPMVHLOSFCPMV / HLOSF
Capitalization7.17M108M7%
EBITDA-1.13M-2.39B0%
Gain YTD65.000-5.363-1,212%
P/E RatioN/AN/A-
Revenue0521M-
Total Cash3.73K8.89B0%
Total Debt1.41M6.1B0%
FUNDAMENTALS RATINGS
CPMV: Fundamental Ratings
CPMV
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
72
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BSBR4.490.02
+0.45%
Banco Santander (Brasil) SA
CIO4.890.02
+0.41%
City Office Reit
MNRO29.09-0.37
-1.26%
Monro
AMS3.05-0.05
-1.46%
American Shared Hospital Services
ALGM19.07-0.76
-3.83%
Allegro MicroSystems

CPMV and

Correlation & Price change

A.I.dvisor tells us that CPMV and RANI have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CPMV and RANI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPMV
1D Price
Change %
CPMV100%
N/A
RANI - CPMV
23%
Poorly correlated
-3.40%
AKESF - CPMV
22%
Poorly correlated
N/A
PPTDF - CPMV
21%
Poorly correlated
N/A
SIGY - CPMV
6%
Poorly correlated
N/A
HLOSF - CPMV
5%
Poorly correlated
N/A
More

HLOSF and

Correlation & Price change

A.I.dvisor tells us that HLOSF and BRTX have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HLOSF and BRTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLOSF
1D Price
Change %
HLOSF100%
N/A
BRTX - HLOSF
23%
Poorly correlated
-3.97%
LGVN - HLOSF
22%
Poorly correlated
-4.81%
ENTBF - HLOSF
7%
Poorly correlated
-0.67%
CPMV - HLOSF
5%
Poorly correlated
N/A
SLN - HLOSF
3%
Poorly correlated
-9.16%
More